Evaxion Biotech A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EVAX research report →
Range $9 – $9
Price Chart
About the company
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers.
- CEO
- Helen Katrina Tayton-Martin
- IPO
- 2021
- Employees
- 46
- HQ
- Horsholm, ND, DK
Get TickerSpark's AI analysis on EVAX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $20.72M
- P/E
- -2.14
- Fwd P/E
- 41.00
- PEG
- -0.01
- P/S
- 2.75
- P/B
- 2.07
- EV/EBITDA
- -0.21
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -122.05%
- Net Margin
- -129.63%
- ROE
- -73.56%
- ROIC
- -35.48%
Latest fiscal year · YoY change
- Revenue
- $7.53M+125.1%
- Gross Profit
- $7.53M+125.1%
- Op Income
- $-9,234,000
- Net Income
- $-7,707,000+27.1%
- EPS
- $-1.21+87.7%
- OCF Growth
- +48.6%
- FCF Growth
- +48.6%
- 52W High
- $12.15
- 52W Low
- $2.52
- 50D MA
- $3.16
- 200D MA
- $4.09
- Beta
- 0.26
- RSI (14)
- 59
- Avg Volume
- 123.16K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the EVAX Q2 '26 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 80.8%
- Shares Outstanding
- 6.32M
- Float Shares
- 5.10M
of shares held by institutions
13 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Telemetry Investments, L.L.C. | 37.50K | ▲ 8.50K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 16, 26 | Bitsch-Norhave Jens | other | 0 |
| Mar 18, 26 | Mattsson Andreas Holm | other | 0 |
| Mar 18, 26 | Mattsson Andreas Holm | other | 0 |
| Jan 1, 22 | Mattsson Andreas Holm | other | 35,000 |
| Jan 1, 23 | Mattsson Andreas Holm | other | 6,250 |
| Jan 1, 24 | Mattsson Andreas Holm | other | 125,000 |
| Jan 1, 24 | Mattsson Andreas Holm | other | 25,000 |
| Dec 21, 23 | Mattsson Andreas Holm | other | 55,147 |
| Jan 31, 25 | Mattsson Andreas Holm | other | 645,700 |
| Mar 18, 26 | Soegaard Marianne | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EVAX coverage
Recent articles, reports, and earnings notes.
No research on EVAX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EVAX report →Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 20
Evaxion announces business update and second quarter 2026 financial results
globenewswire.com · Aug 20
Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
globenewswire.com · Aug 17
Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026
globenewswire.com · Aug 14
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
globenewswire.com · Jul 17
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
globenewswire.com · Jul 12
Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
globenewswire.com · Jul 1
Evaxion receives Prix Galien UK Award for Best digital health solution
globenewswire.com · Jun 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.